Literature DB >> 26686625

RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability.

Edwin Chen1, Jong Sook Ahn2, David B Sykes3, Lawrence J Breyfogle4, Anna L Godfrey2, Jyoti Nangalia2, Amy Ko4, Daniel J DeAngelo5, Anthony R Green2, Ann Mullally6.   

Abstract

JAK2V617F is the most common oncogenic lesion in patients with myeloproliferative neoplasms (MPNs). Despite the ability of JAK2V617F to instigate DNA damage in vitro, MPNs are nevertheless characterized by genomic stability. In this study, we address this paradox by identifying the DNA helicase RECQL5 as a suppressor of genomic instability in MPNs. We report increased RECQL5 expression in JAK2V617F-expressing cells and demonstrate that RECQL5 is required to counteract JAK2V617F-induced replication stress. Moreover, RECQL5 depletion sensitizes JAK2V617F mutant cells to hydroxyurea (HU), a pharmacological inducer of replication stress and the most common treatment for MPNs. Using single-fiber chromosome combing, we show that RECQL5 depletion in JAK2V617F mutant cells impairs replication dynamics following HU treatment, resulting in increased double-stranded breaks and apoptosis. Cumulatively, these findings identify RECQL5 as a critical regulator of genome stability in MPNs and demonstrate that replication stress-associated cytotoxicity can be amplified specifically in JAK2V617F mutant cells through RECQL5-targeted synthetic lethality.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26686625      PMCID: PMC4691544          DOI: 10.1016/j.celrep.2015.11.037

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  25 in total

1.  Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.

Authors:  Elisabetta Antonioli; Alessandra Carobbio; Lisa Pieri; Alessandro Pancrazzi; Paola Guglielmelli; Federica Delaini; Vanessa Ponziani; Niccolò Bartalucci; Lorenzo Tozzi; Alberto Bosi; Alessandro Rambaldi; Tiziano Barbui; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2010-04-23       Impact factor: 9.941

2.  Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

Authors:  Claire N Harrison; Peter J Campbell; Georgina Buck; Keith Wheatley; Clare L East; David Bareford; Bridget S Wilkins; Jon D van der Walt; John T Reilly; Andrew P Grigg; Paul Revell; Barrie E Woodcock; Anthony R Green
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

3.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

4.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

7.  The Rothmund-Thomson syndrome helicase RECQL4 is essential for hematopoiesis.

Authors:  Monique F Smeets; Elisabetta DeLuca; Meaghan Wall; Julie M Quach; Alistair M Chalk; Andrew J Deans; Jörg Heierhorst; Louise E Purton; David J Izon; Carl R Walkley
Journal:  J Clin Invest       Date:  2014-06-24       Impact factor: 14.808

8.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Authors:  Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

9.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

10.  JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.

Authors:  Edwin Chen; Jong Sook Ahn; Charlie E Massie; David Clynes; Anna L Godfrey; Juan Li; Hyun Jung Park; Jyoti Nangalia; Yvonne Silber; Ann Mullally; Richard J Gibbons; Anthony R Green
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-06       Impact factor: 11.205

View more
  14 in total

Review 1.  Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments.

Authors:  Hongwei Liao; Fang Ji; Thomas Helleday; Songmin Ying
Journal:  EMBO Rep       Date:  2018-08-13       Impact factor: 8.807

2.  Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.

Authors:  Megan Bywater; Steven W Lane; Rebecca J Austin; Jasmin Straube; Claudia Bruedigam; Gabor Pali; Sebastien Jacquelin; Therese Vu; Joanne Green; Julius Gräsel; Lianne Lansink; Leanne Cooper; Shin-Jye Lee; Nien-Tsu Chen; Chung-Wei Lee; Ashraful Haque; Florian H Heidel; Richard D'Andrea; Geoff R Hill; Ann Mullally; Michael D Milsom
Journal:  Leukemia       Date:  2019-11-15       Impact factor: 12.883

3.  PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN.

Authors:  Friederike Pastore; Neha Bhagwat; Alessandro Pastore; Aliaksandra Radzisheuskaya; Abdul Karzai; Aishwarya Krishnan; Bing Li; Robert L Bowman; Wenbin Xiao; Aaron D Viny; Anouar Zouak; Young C Park; Keith B Cordner; Stephanie Braunstein; Jesper L Maag; Alexander Grego; Jaanvi Mehta; Min Wang; Hong Lin; Benjamin H Durham; Richard P Koche; Raajit K Rampal; Kristian Helin; Peggy Scherle; Kris Vaddi; Ross L Levine
Journal:  Cancer Discov       Date:  2020-07-15       Impact factor: 38.272

4.  RECQ helicases are deregulated in hematological malignancies in association with a prognostic value.

Authors:  Elena Viziteu; Alboukadel Kassambara; Philippe Pasero; Bernard Klein; Jerome Moreaux
Journal:  Biomark Res       Date:  2016-02-13

5.  Insights into the RecQ helicase mechanism revealed by the structure of the helicase domain of human RECQL5.

Authors:  Joseph A Newman; Hazel Aitkenhead; Pavel Savitsky; Opher Gileadi
Journal:  Nucleic Acids Res       Date:  2017-04-20       Impact factor: 16.971

Review 6.  Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes.

Authors:  Jan Stetka; Jan Gursky; Julie Liñan Velasquez; Renata Mojzikova; Pavla Vyhlidalova; Lucia Vrablova; Jiri Bartek; Vladimir Divoky
Journal:  Cancers (Basel)       Date:  2020-04-07       Impact factor: 6.639

7.  RECQL5 plays an essential role in maintaining genome stability and viability of triple-negative breast cancer cells.

Authors:  Jin Peng; Lichun Tang; Mengjiao Cai; Huan Chen; Jiemin Wong; Pumin Zhang
Journal:  Cancer Med       Date:  2019-06-23       Impact factor: 4.452

8.  Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease.

Authors:  Anja Stirnweiss; Joyce Oommen; Rishi S Kotecha; Ursula R Kees; Alex H Beesley
Journal:  Oncotarget       Date:  2017-12-02

9.  Lnk/Sh2b3 deficiency restores hematopoietic stem cell function and genome integrity in Fancd2 deficient Fanconi anemia.

Authors:  Joanna Balcerek; Jing Jiang; Yang Li; Qinqin Jiang; Nicholas Holdreith; Brijendra Singh; Vemika Chandra; Kaosheng Lv; Jian-Gang Ren; Krasimira Rozenova; Weihua Li; Roger A Greenberg; Wei Tong
Journal:  Nat Commun       Date:  2018-09-25       Impact factor: 14.919

10.  Increased levels of RECQ5 shift DNA repair from canonical to alternative pathways.

Authors:  Henry C Olson; Luther Davis; Kostantin Kiianitsa; Kevin J Khoo; Yilun Liu; Theo A Knijnenburg; Nancy Maizels
Journal:  Nucleic Acids Res       Date:  2018-10-12       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.